Item 7.01 Regulation FD Disclosure.

On November 17, 2022, Jeune Aesthetics, Inc. (the "Company"), a wholly owned subsidiary of Krystal Biotech, Inc., issued a press release announcing positive durability results for KB301 in the PEARL-1 Extension Cohort, an investigational gene-based treatment for improvement of fine lines and wrinkles. In addition, the press release indicated that the Company and Krystal Biotech, Inc. would host an investor conference call at 8:30 a.m. ET on November 17, 2022, to discuss the PEARL-1 durability results and the KB301 clinical development program. For purposes of the call, the Company provided an investor slide presentation (the "Investor Slide Presentation"), which is available on the "Investors" section of Krystal Biotech, Inc.'s website at www.krystalbio.com. Copies of the press release and the Investor Slide Presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.

This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

    Exhibit
      No.              Description

      99.1               Pre    ss Release    , date    d     November 17, 2022
      99.2               Investor Slide Presentation, dated November 2022
      104              Cover Page Interactive Data file (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses